CN101336291A - 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法 - Google Patents

用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法 Download PDF

Info

Publication number
CN101336291A
CN101336291A CNA2006800520283A CN200680052028A CN101336291A CN 101336291 A CN101336291 A CN 101336291A CN A2006800520283 A CNA2006800520283 A CN A2006800520283A CN 200680052028 A CN200680052028 A CN 200680052028A CN 101336291 A CN101336291 A CN 101336291A
Authority
CN
China
Prior art keywords
cell
cells
dendritic cell
antigen
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800520283A
Other languages
English (en)
Chinese (zh)
Inventor
A·L·博因顿
M·L·博希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwest Biotherapeutics LLC
Original Assignee
Northwest Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics LLC filed Critical Northwest Biotherapeutics LLC
Publication of CN101336291A publication Critical patent/CN101336291A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CNA2006800520283A 2005-12-08 2006-12-08 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法 Pending CN101336291A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74888505P 2005-12-08 2005-12-08
US60/748,885 2005-12-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310523196.8A Division CN103589684A (zh) 2005-12-08 2006-12-08 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法

Publications (1)

Publication Number Publication Date
CN101336291A true CN101336291A (zh) 2008-12-31

Family

ID=38123555

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310523196.8A Pending CN103589684A (zh) 2005-12-08 2006-12-08 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法
CNA2006800520283A Pending CN101336291A (zh) 2005-12-08 2006-12-08 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310523196.8A Pending CN103589684A (zh) 2005-12-08 2006-12-08 用于诱导未成熟单核细胞的树突细胞的激活的组合物和方法

Country Status (14)

Country Link
US (2) US20080254537A1 (enExample)
EP (3) EP3072958A1 (enExample)
JP (7) JP5954918B2 (enExample)
KR (6) KR20220113543A (enExample)
CN (2) CN103589684A (enExample)
AR (1) AR056851A1 (enExample)
AU (1) AU2006321794A1 (enExample)
BR (1) BRPI0619499A2 (enExample)
CA (1) CA2632263C (enExample)
CR (1) CR10048A (enExample)
IL (2) IL191930A (enExample)
RU (1) RU2008122550A (enExample)
TW (1) TW200800252A (enExample)
WO (1) WO2007067782A2 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725634A (zh) * 2009-08-24 2012-10-10 纽约市哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
CN103756960A (zh) * 2013-12-04 2014-04-30 深圳市合一康生物科技有限公司 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒
CN103784950A (zh) * 2014-01-22 2014-05-14 北京弘润源生物技术有限公司 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒
CN103800897A (zh) * 2014-03-12 2014-05-21 甘肃中科生物科技有限公司 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
CN102448485B (zh) * 2009-04-09 2015-01-14 墨尔本大学 免疫原性组合物及其用途
CN104936612A (zh) * 2013-09-05 2015-09-23 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
CN105647867A (zh) * 2016-02-28 2016-06-08 深圳爱生再生医学科技有限公司 诱导树突状细胞成熟的方法和树突状细胞
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
WO2016146035A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
AU2013312135B2 (en) * 2012-09-06 2018-02-22 Orbis Health Solutions Llc Tumor lysate loaded particles
CN110042081A (zh) * 2012-12-18 2019-07-23 伊穆尼肯公司 来自异源供体的单核细胞的共分化
CN110106145A (zh) * 2019-06-12 2019-08-09 兰莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
US11248208B2 (en) 2018-03-30 2022-02-15 Syz Cell Therapy Co. Multiple antigen specific cell therapy methods

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
EP2276850B9 (en) * 2008-04-14 2013-10-30 IRX Therapeutics, Inc. Irx-2 modified manufacturing process
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
EP2429585B1 (en) 2009-05-15 2018-04-18 IRX Therapeutics, Inc. Vaccine immunotherapy
US9687537B2 (en) * 2009-07-24 2017-06-27 Rhode Island Hospital Dendritic cell vaccines for asparaginyl-β-hydroxylase expressing tumors
EP2498795B1 (en) 2009-10-12 2016-12-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Granulysin in immunotherapy
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012065156A2 (en) * 2010-11-13 2012-05-18 University Of Florida Research Foundation, Inc. Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
NL2009102C2 (en) * 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
TWI503414B (zh) * 2012-07-05 2015-10-11 Fullhope Biomedical Co Ltd 一種製備專一性ｔ細胞之配方、方法及其配方製備方法
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
EP2931324B1 (en) 2012-12-12 2018-09-19 Orbis Health Solutions LLC Compositions and methods for tissue regeneration
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
CN106687583B (zh) * 2014-06-23 2020-07-24 Jw可瑞基因株式会社 制备树突细胞的方法和包含所述树突细胞的组合物
CN108291204A (zh) * 2015-09-15 2018-07-17 西北生物治疗药物公司 涉及用于患有晚期癌症的受试者的经活化树突状细胞组合物和免疫治疗处理的方法
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
JP6854290B2 (ja) * 2016-09-01 2021-04-07 株式会社理研免疫再生医学 ナチュラルキラーｔ（ｎｋｔ）細胞を刺激する樹状細胞の製造方法、ｎｋｔ細胞を刺激する樹状細胞、ｎｋｔ細胞を刺激する樹状細胞とｎｋｔ細胞とを含む細胞組成物の製造方法およびｎｋｔ細胞を刺激する樹状細胞とｎｋｔ細胞とを含む細胞組成物
EP3518942A4 (en) * 2016-09-29 2020-05-27 Hadasit Medical Research Services&Development Ltd. DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
JP6881331B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881333B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881332B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
US20230173065A1 (en) * 2020-05-15 2023-06-08 Seoul National University R&Db Foundation Composition for enhancing immune response by using activation function of dendritic cells of stromal vascular fractions isolated from adipose tissues
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP1007716A4 (en) * 1997-04-17 2000-06-14 Univ California USE OF LENTIVIRAL VECTORS FOR INTEGRATION INTO DENDRITIC CELLS
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
ES2766299T3 (es) * 2001-09-06 2020-06-12 Northwest Biotherapeutics Inc Composiciones y procedimientos para la activación linfocitaria de células dendríticas monocíticas y células T para generar una respuesta Th-1
ES2755552T3 (es) 2002-06-19 2020-04-22 Northwest Biotherapeutics Inc Dispositivos de filtración de flujo tangencial y métodos para el enriquecimiento de leucocitos
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
AU2004214896A1 (en) * 2003-02-27 2004-09-10 Northwest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
郭建巍等: "人外周血中树突状细胞的诱导及鉴定", 《华西医大学报》 *
陈玉丙等: "小鼠骨髓干细胞体外诱导成熟的树突状细胞对T细胞增殖的影响", 《吉林大学学报（医学版）》 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448485B (zh) * 2009-04-09 2015-01-14 墨尔本大学 免疫原性组合物及其用途
CN102725634A (zh) * 2009-08-24 2012-10-10 纽约市哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
CN102725634B (zh) * 2009-08-24 2016-01-20 纽约哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
AU2013312135B2 (en) * 2012-09-06 2018-02-22 Orbis Health Solutions Llc Tumor lysate loaded particles
CN110042081B (zh) * 2012-12-18 2023-09-01 伊穆尼肯公司 来自异源供体的单核细胞的共分化
CN110042081A (zh) * 2012-12-18 2019-07-23 伊穆尼肯公司 来自异源供体的单核细胞的共分化
CN104936612A (zh) * 2013-09-05 2015-09-23 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
CN103756960A (zh) * 2013-12-04 2014-04-30 深圳市合一康生物科技有限公司 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒
CN103784950A (zh) * 2014-01-22 2014-05-14 北京弘润源生物技术有限公司 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒
CN103800897B (zh) * 2014-03-12 2017-03-22 李金珍 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
CN103800897A (zh) * 2014-03-12 2014-05-21 甘肃中科生物科技有限公司 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
WO2016146035A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CN107735492A (zh) * 2015-03-13 2018-02-23 深圳源正细胞医疗技术有限公司 使用活化t细胞治疗癌的方法
US10967054B2 (en) 2015-03-13 2021-04-06 Syz Cell Therapy Co. Methods of cancer treatment using activated T cells
US11219675B2 (en) 2015-03-13 2022-01-11 Syz Cell Therapy Co. Methods of cancer treatment using activated T cells
US11229689B2 (en) 2015-03-13 2022-01-25 Syz Cell Therapy Co. Methods of cancer treatment using activated T cells
US12312597B2 (en) 2015-03-13 2025-05-27 HRY Z (Shanghai) Biotech Co. Methods of cancer treatment using activated t cells
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
CN105647867A (zh) * 2016-02-28 2016-06-08 深圳爱生再生医学科技有限公司 诱导树突状细胞成熟的方法和树突状细胞
US11248208B2 (en) 2018-03-30 2022-02-15 Syz Cell Therapy Co. Multiple antigen specific cell therapy methods
CN110106145A (zh) * 2019-06-12 2019-08-09 兰莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
CN110106145B (zh) * 2019-06-12 2021-02-12 蓝莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法

Also Published As

Publication number Publication date
EP1957634A4 (en) 2010-01-27
BRPI0619499A2 (pt) 2011-10-04
TW200800252A (en) 2008-01-01
JP2019062904A (ja) 2019-04-25
AU2006321794A1 (en) 2007-06-14
EP3072958A1 (en) 2016-09-28
KR20150082688A (ko) 2015-07-15
CR10048A (es) 2008-09-17
JP5954918B2 (ja) 2016-07-20
WO2007067782A2 (en) 2007-06-14
KR20180049169A (ko) 2018-05-10
IL191930A0 (en) 2008-12-29
CN103589684A (zh) 2014-02-19
EP3805367A1 (en) 2021-04-14
IL229348A0 (en) 2013-12-31
WO2007067782A3 (en) 2008-02-14
JP2009518045A (ja) 2009-05-07
JP2023171524A (ja) 2023-12-01
JP2021045176A (ja) 2021-03-25
IL229348B (en) 2018-12-31
AR056851A1 (es) 2007-10-24
EP1957634A2 (en) 2008-08-20
JP2016105725A (ja) 2016-06-16
JP2017158595A (ja) 2017-09-14
KR20210013327A (ko) 2021-02-03
RU2008122550A (ru) 2010-01-20
US20120244620A1 (en) 2012-09-27
CA2632263C (en) 2022-01-11
JP2013223517A (ja) 2013-10-31
KR20220113543A (ko) 2022-08-12
US20080254537A1 (en) 2008-10-16
KR20240005984A (ko) 2024-01-12
IL191930A (en) 2013-11-28
CA2632263A1 (en) 2007-06-14
KR20080109717A (ko) 2008-12-17

Similar Documents

Publication Publication Date Title
JP2023171524A (ja) 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
US11827903B2 (en) Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
JP2009518045A5 (enExample)
AU2013206016B2 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK40051623A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK1128161A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK1193842A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
MX2008007289A (es) Composiciones y metodos para inducir la activacion de celulas dendriticas monociticas inmaduras
HK1086597B (en) Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128161

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20081231

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1128161

Country of ref document: HK